Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron, an oral ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What’s keeping the pills from taking off?

Matthew Herper covers medical innovation — both its promise and its perils. Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Pfizer’s JAK/TEC inhibitor Litfulo has been ... Given as a once-daily tablet, Litfulo (ritlecitinib) has been recommended by cost-effectiveness agency NICE for use in people aged 12 and over.

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after the failure of its obesity pill. The New York City-based drugmaker’s ...